At doses of 50-100 mg, trazodone increases slow-wave sleep continuity and REM duration, indirectly enhancing glymphatic CSF circulation through the meningeal lymphatic system. However, the human glymphatic system remains poorly validated, with human DCE-MRI studies showing inconsistent results compared to mouse two-photon imaging paradigms. Critically, trazodone's sleep-enhancing effects attenuate within 2-4 weeks of chronic administration (tachyphylaxis), which may preclude sustained disease modification if continuous sleep enhancement is required. The specific dose threshold of ~1 mg/kg for glymphatic effects is not grounded in mechanistic data.
Curated pathway from expert analysis
flowchart TD
A["AQP4<br/>Perivascular Astrocyte Water Channel"]
B["Sleep<br/>Induction"]
C["Glymphatic<br/>Waste Clearance"]
D["Perivascular<br/>Astrocyte End-Feet"]
E["Soluble Amyloid<br/>Tau Clearance"]
F["Neurotoxic<br/>Waste Reduced"]
G["Neuronal<br/>Protection"]
H["Cognitive<br/>Restoration"]
A --> B
B --> C
A --> D
D --> C
C --> E
E --> F
F --> G
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for AQP4 water channels (perivascular astrocyte end-feet), lymphatic endothelial VEGFR3 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for AQP4 water channels (perivascular astrocyte end-feet), lymphatic endothelial VEGFR3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF older adults (60-80 years) with subjective cognitive complaints receive low-dose trazodone (50 mg) nightly for 28 consecutive days, THEN glymphatic clearance markers (CSF Aβ42/Aβ40 ratio, p-tau181) | No significant change in CSF Aβ42/Aβ40 ratio from week 1 (mean change from baseline +2.3%, 95% CI -1.1 to +5.7) to week 4 (mean change from baseline +1.8%, 95% | — no observation — | pending | 0.45 |
| IF healthy adults (40-65 years) receive a single 100 mg dose of trazodone, THEN glymphatic clearance measured by DCE-MRI perivascular CSF influx rate will not correlate with REM duration increase (r < | No significant correlation between REM duration change (delta REM from placebo night) and DCE-MRI perivascular CSF influx rate (Kendall's tau < 0.20, p > 0.15) | — no observation — | pending | 0.35 |